Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Trial status: Open for Enrollment
Why is this study being done?
I. To evaluate disease-free survival with pazopanib (pazopanib hydrochloride) as compared to placebo, defined as the time from randomization to the development of recurrent disease, second primary cancer (other than localized breast, localized prostate, or non-melanoma skin cancer) or death from any cause for patients with metastatic renal cell carcinoma (RCC) with no evidence of disease following metastatectomy.
I. To describe the overall survival of patients with advanced RCC randomly assigned to receive placebo or pazopanib for one year following metastasectomy to no evidence of disease (NED).
II. To describe treatment- and (at recurrence) disease-related adverse events in the two treatment arms III. To analyze quality-adjusted time without symptoms of disease or treatment (Q-TWiST) for subjects in the two treatment arms.
IV. To characterize changes in patient-reported fatigue and (at recurrence) kidney cancer-related symptoms during and following treatment with pazopanib compared to placebo.
V. To explore the association between plasma trough levels of pazopanib and disease-free and overall survival.
VI. To prospectively bank preserved tissue from primary tumors and associated metastatic sites in patients with RCC.
OUTLINE: Patients are randomized to 1of 2 treatment arms.
ARM I: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
Patients may undergo blood sample collection at baseline and periodically during treatment for pharmacokinetic and future correlative studies. Tumor tissue samples may also be collected. Patients complete questionnaires related to mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, along with a question about global health (EQ-5D), the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale, the Patient-Reported Outcome Measurement Information System (PROMIS)-Fatigue scale, and the Functional Assessment of Cancer Therapy Kidney Symptom Index (FKSI-15) at baseline and periodically during study.
After completion of study treatment, patients are followed up every 3 months for up to 10 years.
Who is eligible to participate?
- Patient must have pathologically confirmed renal cell carcinoma with a clear cell component; pure papillary and chromophobe histologies are excluded; there must be pathologic confirmation of metastatic disease in the resected metastasectomy specimen
- Patient must have undergone nephrectomy or partial nephrectomy to remove primary renal cell carcinoma (at any time in the past)
- Patient must have undergone surgical resection to remove one or more sites of metastatic disease, with successful removal of all known sites 2-12 weeks prior to randomization; any number of prior metastatectomies may have been performed in the past, so long as the most recent procedure was within the 12 weeks of registration
- Patients with synchronous disease at initial diagnosis must have metastatic (M1) disease (American Joint Committee on Cancer [AJCC] 7th edition T1-4N0-1M1)
- Positive surgical margins are permitted if the surgeon confirms complete resection of gross metastatic disease, and post-operative scans are negative
- Patients presenting with metachronous disease may have distant metastases, regional lymph node or renal bed recurrence; recurrences at a partial nephrectomy resection site are not eligible if it is the only site of disease
- Patients presenting with tumors within the kidneys (multiple synchronous or single/multiple metachronous) are not eligible if there are no extrarenal sites of disease (i.e. potential multifocal primary disease)
- Patient must have no evidence of disease on post-operative imaging (computed tomography [CT] and/or magnetic resonance imaging [MRI]) conducted within 4 weeks prior to randomization
- Patient must not have received any prior or concurrent systemic therapy for RCC; adjuvant placebo administration is permitted
- Patient must have no active peptic ulcer disease
- Patient must have no active inflammatory bowel disease
- Patient must have no New York Heart Association (NYHA) class II or greater congestive heart failure
- Patient must have no prior history or current clinically apparent central nervous system metastases
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the time of randomization
- Absolute granulocyte count > 1,500/mcL
- Platelets > 100,000/mcL
- Total bilirubin < 1.5 times institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) < 2.5 times upper limit of normal (ULN)
- Calculated creatinine clearance (CrCl) > 30 mL/min
- Subjects must have a urine protein/creatinine (UPC) ratio < 1; if UPC >= 1, then a 24-hour urine total protein must be obtained; subjects must have a 24-hour urine protein value < 1g to be eligible; use of urine dipstick for renal function assessment is not acceptable
- Women must not be pregnant or breast-feeding
- Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study; should a woman become pregnant while participating in this study, she should inform her treating physician immediately; if a man impregnates a woman while participating in this study, he should inform his treating physician immediately
- Patient must be able to swallow pills and have no significant impairment in gastrointestinal absorption including history of gastric bypass surgery
- Patient must have no history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib
- Patient must have no uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patient must have a QTc interval on electrocardiogram (ECG) =< 0.48 seconds by Bazett's calculation (=< Common Terminology Criteria for Adverse Events [CTCAE] v.4 Grade 2) prior to randomization
- Patient must have a systolic blood pressure =< 140 mmHg and diastolic blood pressure must be =< 90 mmHg, measured within 4 weeks prior to randomization; initiation or adjustment of anti-hypertensives prior to starting study treatment is allowed
- Patient must not have serious or non-healing wound, ulcer, or bone fracture at the time of randomization
- Patient must have no history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to randomization
- Patient must have no history of cerebrovascular accident (CVA) within 6 months of randomization
- Patient must have no history of myocardial infarction, hospital admission for unstable angina, cardiac angioplasty or stenting within 6 months of randomization
- Patient must have no history of venous thrombosis within 12 weeks of randomization
- Patient cannot be taking strong CYP3A4 inhibitors such as:
- Antibiotics: clarithromycin, telithromycin, troleandomycin
- Human immunodeficiency virus (HIV) antiviral protease inhibitors: ritonavir, indinavir, saquinovir, nelfinavir, amprenavir, lopinavir
- Antifungals: itraconazole, ketoconazole, voriconazole, fluconazole
- Antidepressants: nefazodone
- Patient must not have history of hemoptysis in excess of 2.5 mL (1/2 teaspoon) within 8 weeks prior to randomization
- Patient must not be taking drugs known to prolong the QTc interval; such drugs should be discontinued at least 5 half-lives prior to randomization
- Patient must be able to receive either CT with IV contrast or MRI with gadolinium
- Patients must not have any history of other cancer within 3 years from time of randomization with the exception of basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or resected non-invasive (Ta) urothelial carcinoma